Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor

Laetitia J. Martin(Boehringer Ingelheim (Austria)), Darryl B. McConnell(Boehringer Ingelheim (Austria)), Stefan Knapp(Goethe University Frankfurt), Christopher R. Vakoc(Cold Spring Harbor Laboratory), Guido Boehmelt(Boehringer Ingelheim (Austria)), Stefan Kornigg(Boehringer Ingelheim (Austria)), Dirk Kessler(Boehringer Ingelheim (Austria)), Catherine Rogers(University of Alabama at Birmingham Hospital), Dennis Fiegen(Boehringer Ingelheim (Germany)), Marco H. Hofmann(Boehringer Ingelheim (Austria)), Herbert Nar(Boehringer Ingelheim (Germany)), Gerd Bader(Boehringer Ingelheim (Austria)), Klaus Rumpel(Boehringer Ingelheim (Austria)), Anja Hohmann(Sarepta Therapeutics (United States)), Manfred Koegl(Boehringer Ingelheim (Austria)), Steffen Steurer(Boehringer Ingelheim (Austria)), Thomas Gerstberger(Boehringer Ingelheim (Austria)), Petr Knesl(Boehringer Ingelheim (Austria)), Andreas Zoephel(Boehringer Ingelheim (Austria)), Otmar Schaaf(Boehringer Ingelheim (Austria)), C. Tallant(University of Oxford), O. Fedorov(University of Oxford), Xiaoling Cockcroft(Boehringer Ingelheim (Austria)), Mark Pearson(Boehringer Ingelheim (Austria)), Susanne Müller(Goethe University Frankfurt), Markus Zeeb(Boehringer Ingelheim (Germany))
Journal of Medicinal Chemistry
February 25, 2016
Cited by 227


Related Papers